Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is ...
Oct 16 (Reuters) - The U.S. Food and Drug Administration on Monday approved the expanded use of Merck & Co's (MRK.N), opens new tab blockbuster immunotherapy Keytruda in early-stage patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback